Pharmaceutical follow-up of patients treated in primary care
Not Applicable
- Conditions
- nified Health SystemPrimary Health CareDiabetes MellitusN02.278.216.500.968.603
- Registration Number
- RBR-85kg336
- Lead Sponsor
- niversidade Federal de São João del-Rei (UFSJ)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
In the first phase, pharmacists who work in Primary Health Care of the Unified Health System of the participating municipalities will be included. There are no exclusion criteria at this stage. In the second phase, patients aged 18 years or older with type I Diabetes Mellitus will be included; or type II; or gestational; or adult latent autoimmune diabetes, known as the LADA type; or Maturity Onset Diabetes of the Young MODY; and who are using at least one drug for the treatment of Diabetes Mellitus
Exclusion Criteria
Second phase: patients who are not responsible for their own pharmacotherapy and who do not have a caregiver to accompany them to consultations
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Check whether there was a reduction in glycated hemoglobin in the eight-month period (one visit per month) of patients in the intervention group compared to the control group (and whether such a reduction is statistically significant), by requesting tests.
- Secondary Outcome Measures
Name Time Method Assess the quality of life before and after the intervention using The World Health Organization Quality of Life assessment, in its abbreviated form (WHOQOL-bref).<br>;Assess adherence to treatment before and after the intervention using the Morisky-Green test.;Count and describe the interventions performed by pharmacists.;Know the main types of pharmacotherapeutic problems.